Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on enzymatic transamination. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN118726300A reveals a novel transaminase mutant for producing agrochemical intermediates with high optical purity and reduced manufacturing costs.
Patent CN106754806B discloses a high-efficiency transaminase for synthesizing (R)-3-aminobutanol, offering superior substrate tolerance and eliminating organic cosolvents for cost-effective manufacturing.
Patent CN113789310B reveals high-yield transaminase route for moxifloxacin intermediates, eliminating DMSO for cost-effective and scalable API manufacturing.
Novel enzymatic route for Sitagliptin key intermediate reduces costs and eliminates heavy metals. Ideal for reliable pharmaceutical intermediate suppliers seeking scalable API manufacturing solutions.
Novel enzymatic route for tofacitinib intermediate offers high purity and yield. Reduces cost and waste for pharmaceutical manufacturing supply chains.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediate synthesis, offering superior conversion rates and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN112930348A details an enzymatic route for Safraninib, improving yield and reducing waste compared to chiral resolution methods.
Solve PF-07321332 synthesis challenges: 76%+ yield, 98% purity, mild conditions. Eliminate -78°C steps & column chromatography. Scale to 100MT/yr.